ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 77 filers reported holding ORIC PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $6,095,829 | -22.0% | 1,007,575 | 0.0% | 3.82% | -8.6% |
Q2 2023 | $7,818,782 | +36.1% | 1,007,575 | 0.0% | 4.18% | +11.8% |
Q1 2023 | $5,743,178 | -3.2% | 1,007,575 | 0.0% | 3.74% | +18.5% |
Q4 2022 | $5,934,617 | +84.1% | 1,007,575 | 0.0% | 3.16% | +78.4% |
Q3 2022 | $3,224,000 | -28.6% | 1,007,575 | 0.0% | 1.77% | -35.0% |
Q2 2022 | $4,514,000 | -16.1% | 1,007,575 | 0.0% | 2.72% | +13.8% |
Q1 2022 | $5,380,000 | -63.7% | 1,007,575 | 0.0% | 2.39% | -46.8% |
Q4 2021 | $14,811,000 | -29.7% | 1,007,575 | 0.0% | 4.50% | -20.3% |
Q3 2021 | $21,068,000 | +18.2% | 1,007,575 | 0.0% | 5.64% | +58.9% |
Q2 2021 | $17,824,000 | -27.8% | 1,007,575 | 0.0% | 3.55% | -37.2% |
Q1 2021 | $24,686,000 | -27.6% | 1,007,575 | 0.0% | 5.66% | -60.3% |
Q4 2020 | $34,106,000 | +35.3% | 1,007,575 | -0.0% | 14.26% | +17.6% |
Q3 2020 | $25,199,000 | -25.9% | 1,007,576 | 0.0% | 12.12% | -1.3% |
Q2 2020 | $33,986,000 | – | 1,007,576 | – | 12.28% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Memorial Sloan Kettering Cancer Center | 602,272 | $3,643,746 | 14.84% |
Column Group LLC | 3,568,181 | $21,587,495 | 14.33% |
Nextech Invest Ltd. | 4,285,714 | $25,928,570 | 7.86% |
Prosight Management, LP | 2,579,802 | $15,607,802 | 4.95% |
Invus Financial Advisors, LLC | 1,007,575 | $6,095,829 | 3.82% |
SILVERARC CAPITAL MANAGEMENT, LLC | 1,123,345 | $6,796,237 | 2.06% |
VR Adviser, LLC | 2,142,856 | $12,964,279 | 1.36% |
Altium Capital Management LP | 418,706 | $2,533,171 | 1.32% |
Euclidean Capital LLC | 1,978,820 | $11,971,862 | 1.31% |
Frazier Life Sciences Management, L.P. | 2,142,855 | $12,964,273 | 0.86% |